COVID-19 pandemic highlights the urgent global need to control air pollution

Beth Israel Lahey Health

Newswise — Boston, Mass. – More than 91 percent of the world’s population lives in areas that exceed air quality guidelines recommended by the World Health Organization, and more people are impacted by worsening air quality each year. Ambient air pollution – including potentially harmful pollutants such as small particles and toxic gases emitted by industries, households, cars and trucks – has been shown to worsen viral respiratory infections. Now, new studies are showing a similar association between ambient air pollution and worse COVID-19 outcomes.

In a new commentary reviewing current research on the potential relationships among pollution, respiratory viruses and health disparities, physician-researchers at Beth Israel Deaconess Medical Center (BIDMC) discuss several ways that the COVID-19 pandemic highlights the urgent need to address the global problem of air pollution and improve respiratory health and equity worldwide. The commentary appears in the Annals of the American Thoracic Society.

“A multitude of studies show that exposure to higher long-term ambient air pollution is associated with both increased risk of infection and death from COVID-19,” said corresponding author Stephen Andrew Mein, MD, a physician in BIDMC’s Department of Medicine. “Historically, air pollution has been linked with worse health outcomes, including higher mortality, due to other respiratory viruses like influenza. Now, new research on COVID-19 adds further evidence of the adverse effects of ambient air pollution and the urgent need to address the public health crisis of pollution.”

In one of the most prominent studies modeling COVID-19 mortality Mein and colleagues reviewed, researchers  at the Harvard T.H. Chan School of Public Health found that each small (1 mg/m3) increase in long-term fine inhalable particle (PM2.5) exposure was associated with an eight percent increase in mortality during the pandemic, per an examination of county level data.  Another study concluded that air pollution has contributed 15 percent to COVID-19 mortality worldwide.

“The studies we reviewed evaluated whether long-term, ambient air pollution exposure that occurred years prior to the pandemic was associated with worse COVID-19 outcomes,” said Mein, who is also an Instructor in Medicine at Harvard Medical School.

The exact mechanisms of the association between long-term pollution and poor COVID-19 outcomes are not fully known. However, scientists have suggested that long-term exposure to air pollution may impair the immune system, leading both to increased susceptibility to viruses and to more severe viral infections.  Higher air pollution exposure — a burden disproportionately shouldered by communities of color in the Unites States — is also associated with higher rates of heart disease and metabolic disorders such as diabetes, which are known to be risk factors for severe disease and death from COVID-19.  These long-term chronic effects occurred well in advance of the reported reductions in air pollution during the COVID-19 pandemic.

The authors noted that recent models predict that improved air quality (due to less travel and industrial activity) during the pandemic may have reduced morbidity and mortality from non-communicable diseases, but more study is necessary.

“Research evaluating associations between the dramatic reduction in ambient air pollution during global lockdowns and health care utilization for respiratory conditions would further confirm the impact of ambient air pollution on non-communicable diseases and the need to reduce air pollution to improve overall health,” said Mary Rice, MD, physician in the Pulmonary, Critical Care & Sleep Medicine Department at BIDMC and senior author of the commentary.

“While the primary association between air pollution and COVID-19 outcomes has been generally consistent, there is still much research to be done,” added Rice, who is also Assistant Professor in Medicine at Harvard Medical School.  “In particular, there is a need for studies that adjust for individual-level risk factors, since current studies have been restricted to county or municipal-level exposure and outcome data. Research is also needed to evaluate whether air pollution contributes to the stark differences in COVID-19 outcomes among communities of color.

Racially and ethnically diverse communities are more likely to be located in areas closer to industrial pollution such as PM2.5 and nitrogen dioxide, and to work in types of businesses that expose them to more air pollution. These inequalities in residential and occupational air pollution exposure may be one of the causes of the stark disparities of the COVID-19 pandemic along racial and ethnic lines.

“The COVID-19 pandemic has highlighted the widespread health consequences of ambient air pollution, including acute effects on respiratory immune defenses and chronic effects that lead to higher risk of chronic cardiopulmonary disease and acute respiratory distress syndrome (ARDS),” said Mein. “These chronic health effects likely explain the higher COVID-19 mortality among those exposed to more air pollution. The pandemic has also provided a glimpse into the health benefits of cleaner air. COVID-19 is a wakeup call for the need to adopt stricter air quality standards and end our tolerance for pollution in disadvantaged neighborhoods. As part of our post-COVID-19 recovery, we must clean up the air to improve respiratory health and equality worldwide.”

Editor’s note: This release is adapted from a press release issued by the American Thoracic Society.

About Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding. BIDMC is the official hospital of the Boston Red Sox. For more information, visit www.bidmc.org.

Beth Israel Deaconess Medical Center is a part of Beth Israel Lahey Health, a new health care system that brings together academic medical centers and teaching hospitals, community and specialty hospitals, more than 4,000 physicians and 35,000 employees in a shared mission to expand access to great care and advance the science and practice of medicine through groundbreaking research and education.

###

SEE ORIGINAL STUDY




Filters close

Showing results

110 of 5584
Released: 7-May-2021 1:40 PM EDT
There is no evidence that vaccines could cause harm to people who have recovered from COVID-19
Newswise

An article published by Robert F. Kennedy Jr.’s anti-vaccination organization and widely shared on social media questions the need of vaccinating those who’ve already recovered from COVID-19. The article says there’s a "potential risk of harm, including death" in getting the vaccines. We report this claim as false. There is no evidence that vaccinating people who had previously had COVID is resulting in an increased risk of adverse events.

Newswise: Abbott.jpg
Released: 7-May-2021 1:00 PM EDT
FSU expert available to discuss intellectual property and COVID-19 vaccines
Florida State University

By: Bill Wellock | Published: May 7, 2021 | 11:55 am | SHARE: President Joe Biden has expressed his support for a World Trade Organization proposal to waive intellectual property rights for COVID-19 vaccines.Florida State University law professor Frederick Abbott, the Edward Ball Eminent Scholar Professor of International Law, is available to comment on international intellectual property rights and global economic issues around the proposal.

access_time Embargo lifts in 2 days
Embargo will expire: 11-May-2021 11:00 AM EDT Released to reporters: 7-May-2021 1:00 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 11-May-2021 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 7-May-2021 11:15 AM EDT
Asthma attacks plummeted among Black and hispanic/latinx individuals during the COVID-19 pandemic
Brigham and Women’s Hospital

Asthma attacks account for almost 50 percent of the cost of asthma care which totals $80 billion each year in the United States

access_time Embargo lifts in 2 days
Embargo will expire: 11-May-2021 11:00 AM EDT Released to reporters: 7-May-2021 10:40 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 11-May-2021 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 7-May-2021 9:00 AM EDT
Navigating the COVID-19 crisis to prevent pressure injuries: Learning health system helped one hospital adapt and update care in real time
Wolters Kluwer Health: Lippincott

Early in the COVID-19 pandemic, healthcare systems scrambled to modify patient care processes – particularly when it came to strategies aimed at reducing the risk of hospital-related complications. A look at how one hospital applied its learning health system (LHS) framework to respond to a COVID-19-related increase in hospital-acquired pressure injuries (HAPIs) is presented in the May/June Journal for Healthcare Quality (JHQ), the peer-reviewed journal of the National Association for Healthcare Quality (NAHQ). The journal is published in the Lippincott portfolio by Wolters Kluwer.

Newswise: Ultra-Fast COVID-19 Sensor Invented at Texas Tech Gets Boost Into International Markets
Released: 7-May-2021 8:55 AM EDT
Ultra-Fast COVID-19 Sensor Invented at Texas Tech Gets Boost Into International Markets
Texas Tech University

EviroTech LLC announced today (May 7) a $4 million investment into the company by 1701 Ventures GmbH of Göttingen, Germany, which will allow EviroTech to complete the final design, production startup and market introduction of its Ultra-Fast COVID-19 detection sensor.

Released: 7-May-2021 7:05 AM EDT
Rutgers Recruiting Participants for Pfizer COVID-19 Pediatric Vaccine Clinical Trial
Rutgers University-New Brunswick

Rutgers has been selected as a clinical trial site for the global Pfizer-BioNTech research study to evaluate the efficacy of its COVID-19 vaccine in children ages 6 months to 11 years. This is the third time Rutgers has served as a COVID-19 vaccine clinical trial site for pharmaceutical companies. Last fall, it conducted trials for Moderna and Johnson & Johnson.


Showing results

110 of 5584

close
1.07397